Study picks out children with incurable brain cancer who could benefit from adult therapy

May 14, 2018, Institute of Cancer Research

Children with incurable brain tumours could benefit from potentially life-extending treatment if genetic testing was used to personalise therapy as it is in many adults, major new research reports.

Scientists analysed the DNA of children taking an adult drug on a clinical trial deemed to have 'failed', and found that many with particular genetic traits had actually responded well to treatment.

Some of these children survived more than a year longer than others on the trial.

The international study—led by a team at The Institute of Cancer Research, London, and involving 51 centres in 14 countries—found that children whose tumours had in the MAPK network of genes benefited from Avastin (bevacizumab) alongside standard treatment.

In these children, Avastin also appeared to cause to flood in to help destroy their tumours—raising the possibility that they could be good candidates for future immunotherapy.

Children's aggressive, or 'high grade', are currently treated as one disease, but a recent genetic analysis by the same team at The Institute of Cancer Research (ICR) showed they were actually at least 10 different diseases.

The new research shows the benefits of testing children for genetic mutations in their tumours to make sure they receive the treatment most likely to work.

Increasingly, treatment of adult cancers is shaped by , but children's cancer continues to lag behind.

The new independent academic study—published today (Monday) in the prestigious journal Cancer Cell and funded by Roche—analysed genetic, molecular and immunology data from the HERBY phase II clinical trial after it had been completed.

The researchers will now look to confirm the findings in a clinical trial set up specifically to test the effectiveness of Avastin in children with these mutations. If successful, it would open up a whole new treatment option for a disease with very few effective therapies.

This trial compared Avastin combined with standard treatment of temozolomide and radiotherapy with standard treatment alone in 121 children aged three to 18 with high-grade tumours.

The trial found that, overall, children did not benefit from the addition of adult cancer drug Avastin—a drug that works by blocking a tumour's blood supply and drawing the immune system to the cancer.

But looking deeper into the genetics of the tumours revealed that children taking Avastin whose tumours had mutations in the MAPK network of genes—around 10-15 per cent of the total—survived up to 16 months longer than other patients.

These children also saw many more immune cells called killer T cells flock to the site of their tumours—in some cases because their cancers had more mutations overall and so were easier for the immune system to pick apart from healthy cells.

Children with these tumours could potentially be considered for future clinical of immunotherapies, which tend to work best in patients whose cancers have already sparked some immune reaction.

Children with tumours that were driven by mutations in the histone H3F3FA gene did not benefit from Avastin, with an average survival of only 7.9 months, and there were very few immune cells present in and around the .

Researchers at the ICR—a research institute and charity—believe that testing for mutations could help direct treatment so some children are picked out for Avastin, and others spared treatment that is very unlikely to work for them.

Although rare, aggressive childhood brain tumours are the biggest cause of cancer-related death under 19 years of age because survival rates are so poor—children with these tumours are only expected to live an average of nine to 15 months.

Study leader Professor Chris Jones, Professor of Childhood Brain Tumour Biology at The Institute of Cancer Research, London, said: "We will never see progress in treatment of children's brain cancers while we continue to lump everyone with these cancers together in one group. Children deserve better.

"Our research has previously shown that children's brain cancer is really 10 different diseases, and our new study found these genetic differences can have a major impact on how children respond to drugs. We are building up evidence that genetic testing in children with cancer can have real benefits for selecting the best treatment.

"The next step is to confirm our findings in a clinical trial where only children with these specific mutations receive Avastin. If that is successful, we can open up a promising new option for paediatric brain cancer by turning an established drug for adult cancers into a targeted treatment for children."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: "We've seen dramatic progress in the treatment of adult cancers, through advances such as the introduction of targeted therapies and more recently immunotherapies. But that progress hasn't yet been matched in children.

"This exciting research is giving us the tools to personalise for children with brain cancer. It's vital that we take advantage of advances in research by improving 's access to genetic testing and , so every child has the best possible chance of receiving a drug that may work for them."

Explore further: Potential treatment for brain cancer as drug shrinks tumours

Related Stories

Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017
An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

Study splits incurable childhood brain tumors into 10 new diseases

September 28, 2017
Scientists have found that deadly childhood brain tumours are actually 10 different diseases that should each be diagnosed and treated based on their specific genetic faults.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Children with cancer to get new gene test

March 31, 2016
Children with cancer at leading hospitals across the UK will be offered testing for genetic mutations in their tumours as part of a new initiative to begin to personalise children's cancer treatment.

Researchers show aspirin added to cancer drug improves effectiveness

December 4, 2017
Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.

Immunotherapy treatment option for selected breast cancer patients, genetic study suggests

September 13, 2017
Immunotherapy drugs could help some breast cancer patients based on the genetic changes in their tumours, researchers at the Wellcome Trust Sanger Institute and their collaborators find. Published today (13 September) in ...

Recommended for you

Revealing the molecular mystery of human liver cells

October 22, 2018
A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular ...

New tool gives deeper understanding of glioblastoma

October 22, 2018
Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

New drug combination destroys chemo-resistant blood cancer

October 22, 2018
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients ...

Major trial shows targeted drug extends breast cancer survival

October 22, 2018
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.